Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Transcatheter Aortic Valve Implantation (TAVI)

1-year results of the SAPIEN 3 study

    • Cardiology
    • Congress Reports
    • News
    • RX
    • Studies
  • 3 minute read

At EuroPCR, the Congress of Interventional Medicine, held in Paris in May 2015, the latest results of various studies on TAVI (transcatheter aortic valve implantation) were presented, among other topics. These included results from the 1-year follow-up of the SAPIEN 3 trial and early data from intermediate-risk TAVI patients.

The Edwards SAPIEN 3 valve represents the latest generation of aortic valve prostheses delivered via transcatheter aortic valve implantation (TAVI). This procedure is primarily used to treat aortic stenosis in patients at high surgical risk. In intermediate-risk patients, TAVI is currently under discussion.

High survival rates after TAVI

The ongoing prospective, multicenter, nonrandomized SAPIEN 3 trial is evaluating outcomes, survival rates, and adverse event rates of TAVI with the SAPIEN 3 valve – the latest results, collected after 1-year follow-up, were presented by John Webb, MD, St. Paul’s Hospital, Vancouver, Canada, at the EuroPCR Congress. Data from 150 patients with severe aortic stenosis and high (STS score ≥8 or EuroSCORE ≥15) or intermediate (STS score ≥4 or EuroSCORE ≥10) surgical risk were analyzed. These patients were treated with the SAPIEN 3 valve between January and November 2013 in 16 centers in Germany, Italy, France, the United Kingdom and Canada. Access was transfemoral in 96 (64%) patients and transapical or transaortic in 54 (36%).

The 1-year survival rate of transfemoral-treated patients was 91.6%. This is the highest 1-year survival rate ever achieved in a multicenter TAVI trial. The figure is particularly remarkable when one considers the average age of the study participants: After all, it is 83.6 years.

There were many comorbidities in the study population and the mean EuroSCORE score was high: 19.8 in the transfemoral group, 24.9 in the transapical or transaortic group. Nevertheless, TAVI patients had a survival rate almost as good as the normal population, in which the 1-year survival rate of 84-year-old individuals is 92.5%.

Risk for stroke is low

The incidence of stroke in the transfemoral access patient group was 2.1% (with 1.1% with permanent disability), which was very low. In the period between day 30 and one year after the intervention, only one patient had suffered a stroke. Mild or moderate paravalvular leakage occurred in 2% of patients during the first year after TAVI, but severe cases of paravalvular leakage did not occur within the study; there was also no case of valve thrombosis or valve displacement.

Good hemodynamic function of the implanted aortic valves was preserved in all patients at 1 year: 37% of patients were in NYHA class I, 56.5% in class II, 4.8% in class III, and 0.8% in class IV (before the procedure class I: 0%, class II: 16.1%, class III: 77.4%, class IV: 6.5%).

All-cause mortality at one year was 8.4% (cardiac mortality 2.1%) in the transfemoral access group and 24.3% (cardiac mortality 13.3%) in the other access group. A permanent pacemaker had to be used in 15.7% (transfemoral access) resp. 19.8% (other access) of patients were used.

TAVI also for patients with intermediate surgical risk?

Currently, the SAPIEN 3 valve is approved in Europe for the treatment of patients with aortic stenosis who are inoperable or patients at high surgical risk. Given the good results in these patients, the question is whether TAVI might not be an alternative to surgery for older patients with severe aortic stenosis and intermediate risk, Dr. Webb said. The first results of the corresponding study (extension of the SAPIEN 3 study) were also presented at the congress.

The multicenter study followed 101 patients with severe aortic stenosis and intermediate surgical risk (STS score ≥4 and ≤8 or EuroSCORE ≥10 and ≤15) from 13 centers in Europe and Canada. All-cause mortality was 1% at 30 days after TAVI. Significant complications occurred infrequently: stroke in 2% of patients, major vascular events in also 2%, new implantation of a permanent pacemaker in 4%, moderate paravascular leaks in 2.3%, and no severe leaks. These early results suggest a high safety of TAVI even in patients with intermediate surgical risk.

Source: EuroPCR, Congress of Interventional Medicine, May 17-20, 2015, Paris.

 

HAUSARZT PRAXIS 2015; 10(7): 24-25
CARDIOVASC 2015; 14(4): 30-31
 

Autoren
  • Dr. med. Eva Ebnöther
Publikation
  • HAUSARZT PRAXIS
Related Topics
  • Heart valve
  • Sapien
  • Stroke
  • Stroke
  • TAVI
Previous Article
  • Interdisciplinary Symposium Neuro Emergencies

Seizure events and confusional states – how to proceed?

  • Congress Reports
  • Neurology
  • RX
View Post
Next Article
  • Breast cancer in the family

Is the prognosis worsening?

  • Gynecology
  • News
  • Oncology
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.